Tumor Tissue Collection

PROCEDURE4 trials

Sponsors

Medical University of Vienna, Memorial Sloan Kettering Cancer Center, Merck Sharp & Dohme LLC, University of California, San Francisco

Conditions

Breast NeoplasmsCarcinoma, Non-Small-Cell LungColorectal NeoplasmsCutaneous Squamous Cell Carcinoma (CSCC)Endocrine Gland NeoplasmsLung NeoplasmsNeoplasms of the Female GenitaliaOvarian Neoplasms

Unknown Phase

Establishment of a Tumor Bank for Tissue Samples

RecruitingNCT01789229

Medical University of ViennaBreast Neoplasms, Colorectal Neoplasms, Endocrine Gland Neoplasms +3

Start: 2003-09-30End: 2026-12-31Target: 10000Updated: 2023-03-23

A Study of Blood Based Biomarkers for Pancreas Adenocarcinoma

RecruitingNCT03334708

Memorial Sloan Kettering Cancer CenterPancreatic Cancer, Pancreatic Cyst, Pancreatic Diseases +1

Start: 2017-10-30End: 2026-10-30Target: 700Updated: 2025-12-02

KEYMAKER-U01 Umbrella Master Study: Studies of Investigational Agents With Either Pembrolizumab (MK-3475) Alone or With Pembrolizumab PLUS Chemotherapy in Participants With Non-small Cell Lung Cancer (NSCLC) (MK-3475-U01/KEYMAKER-U01)

RecruitingNCT04165798

Merck Sharp & Dohme LLCCarcinoma, Non-Small-Cell Lung

Start: 2019-12-19End: 2032-02-13Target: 1065Updated: 2026-04-02

Tumor-Informed ctDNA Testing for MRD Following Treatment of Squamous Cell Carcinoma

RecruitingNCT06606028

University of California, San FranciscoCutaneous Squamous Cell Carcinoma (CSCC), Squamous Cell Carcinoma Head and Neck Cancer (HNSCC), Squamous Cell Carcinoma of Head and Neck +1

Start: 2024-10-09End: 2029-12-30Target: 250Updated: 2025-12-12

Related Papers

Abstract CT249: Results from KEYMAKER-U01 substudy 3: a phase 2 umbrella study of pembrolizumab plus investigational agents in patients with non-small-cell lung cancer (NSCLC) previously treated with anti-PD-(L)1 therapy

Cancer Research2024-04-051 citations